** Shares of biotech VBI Vaccines rise 21.2% to 80 cents premarket
** Co enters into licensing agreement with private firm Brii Biosciences, under which Brii will acquire intellectual property for VBIV's experimental therapy to treat hepatitis B
** Co will also sell its Rehovot, Israel manufacturing facility and certain related assets under agreement
** Brii Bio will develop and market VBIV's experimental cancer therapy in the Asia Pacific region, excluding Japan
** VBIV to receive up to $33 mln in payments, subject to achievement of certain milestones
** On completion of the transaction, co's total debt to reduce to $17 mln - VBIV
** Stock fell about 96% in the last 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Comments